🏛️ Verified NIH Record • Updated 2026-03-04

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 (NCT07153172)

Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Novo Nordisk A/S

🩺 Plain-English Summary (8th-Grade Level)

The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.

Who can join: Review the eligibility criteria below.

Location: Syneos Health Clinique — Québec

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

  • Syneos Health Clinique — Québec,

📞 Contact the Study Coordinator

Phone: (866) 867-7178

Email: clinicaltrials@novonordisk.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Obesity clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗